Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Prexasertib (dihydrochloride)

Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of 50=8 nM) and RSK1 (IC50=9 nM) . Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity[1][2].

Product Specifications

CAS Number

[1234015-54-3]

Product Name Alternative

LY2606368 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Checkpoint Kinase (Chk)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LY2606368-dihydrochloride.html

Purity

99.73

Solubility

DMSO : 8 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

NCCCOC(C=CC=C1OC)=C1C2=CC(NC3=NC=C(C#N)N=C3)=NN2.[H]Cl.[H]Cl

Molecular Formula

C18H21Cl2N7O2

Molecular Weight

438.31

Precautions

H302, H315, H319, H335

References & Citations

[1]King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14 (9) :2004-1|[2]Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7 (3) :473-483.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

Chk1; Chk2

Citation 01

BioRxiv. September 10, 2021.|Methods Mol Biol. 2018:1711:351-398.|Neurooncol Adv. 2024 Nov 19;6 (1) :vdae187.|Sci Rep. 2025 Nov 27.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|bioRxiv. 2025 April 17.|bioRxiv. January 04, 2022.|Br J Cancer. 2021 Jul;125 (1) :101-111.|Cancers (Basel) . 2021 Aug 20;13 (16) :4200.|Cancers. 2020 Aug 26;12 (9) :2426.|Cancers. 2020 Jun 29;12 (7) :1726.|Cell Biol Toxicol. 2023 Jun;39 (3) :795-811.|Cell Rep. 2025 Apr 17;44 (5) :115605.|Cell Signal. 2025 Jul:131:111709.|Cells. 2024 Apr 19;13 (8) :710.|Eur J Pharmacol. 2025 Sep 15:1003:177942.|Int Immunopharmacol. 2025 Mar 26:150:114278.|Mol Cancer Res. 2019 Oct;17 (10) :2102-2114.|Mol Cancer Ther. 2025 Jun 4;24 (6) :920-930.|Nat Commun. 2019 Aug 2;10 (1) :3485.|Oncogene. 2022 Nov;41 (46) :5020-5031.|Oncogenesis. 2025 Mar 1;14 (1) :4.|Patent. US20210353605A1.|Research Square Preprint. 2021 May.|Research Square Preprint. 2024 Nov 06.|Sci Rep. 2021 Feb 4;11 (1) :3176.|Thorax. 2022 Mar;77 (3) :247-258.|Universität Hamburg. Elektronische Dissertationen und Habilitationen. 2022 Aug.|Utrecht University. 2023 Feb.

Available Sizes

More Discoveries

Explore Other Products

Browse additional items from our catalog

LOC100504799 3'UTR GFP Stable Cell Line

TU162169 1.0 mL

LOC100504799 3'UTR GFP Stable Cell Line

Sign In for Pricing

Slc34a2 (NM_011402) Mouse Tagged ORF Clone Lentiviral Particle

MR210105L4V 200 µL

Slc34a2 (NM_011402) Mouse Tagged ORF Clone Lentiviral Particle

Sign In for Pricing

Type-2 Angiotensin II Receptor (AGTR2) Antibody

abx421478-01 50 µg

Type-2 Angiotensin II Receptor (AGTR2) Antibody

Sign In for Pricing

Type-2 Angiotensin II Receptor (AGTR2) Antibody

abx421478-02 100 µg

Type-2 Angiotensin II Receptor (AGTR2) Antibody

Sign In for Pricing

Anti-PAK4/5 Antibody

CPA5903-01 30 µL

Anti-PAK4/5 Antibody

Sign In for Pricing

Anti-PAK4/5 Antibody

CPA5903-02 50 μL

Anti-PAK4/5 Antibody

Sign In for Pricing